Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 4/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097207 | 0.78 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7793203 | 0.72 | CA1 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6745289 | 0.70 | GAA (0.66) | MMP2MMP9MMP8MMP13GAA | |
| SCHEMBL6652305 | 0.70 | CALM1 (0.58) | MMP2MMP9MMP8MMP13CALM1 | |
| SCHEMBL7794122 | 0.69 | CA12 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11495470 | 0.69 | MAOB (0.56) | MMP2MMP9MMP8MMP13CALM1 | |
| SCHEMBL3571823 | 0.69 | CA1 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2259946 | 0.67 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5701180 | 0.67 | PPARG (0.58) | MAPTSMN1; SMN2 | |
| SCHEMBL7836795 | 0.67 | APLNR (0.42) | MMP8MMP13CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030125329-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-07-03 | — | — | US | claimed |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-07-03 | — | — | US | claimed |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-26 | — | — | US | claimed |
| US-20030114454-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-06-19 | — | — | US | claimed |
| US-20030109528-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-06-12 | — | — | US | claimed |
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-05 | — | — | US | claimed |
| US-20030100559-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-05-29 | — | — | US | claimed |
| US-20030096818-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-22 | — | — | US | claimed |
| US-20030087905-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-05-08 | — | — | US | claimed |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-01 | — | — | US | claimed |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-02-13 | — | — | US | claimed |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| US-6765023-B2 | SUCH AS 3-((3-(3-TRIFLUOROMETHOXYPHENOXY)PHENYL)((3-(1,1,2,2-TETRAFLUOROETHOXY) -PHENYL)METHYL) AMINO)-1,1,1-TRIFLUORO-2-PROPANOL FOR TREATING CARDIOVASCULAR DISORDERS AND DYSLIPIDEMIA | PFIZER, INC. | 2004-07-20 | — | — | US | disclosed |
| US-6723753-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES. | PHARMACIA CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-20020120011-A1 | Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-08-29 | — | — | US | disclosed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114454-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MMP2 1671/4885MMP9 2765/4885MMP8 2164/4885 |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MMP2 1671/4885MMP9 2765/4885MMP8 2164/4885 |
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MMP2 1671/4885MMP9 2765/4885MMP8 2164/4885 |
| US-20030096818-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MMP2 1671/4885MMP9 2765/4885MMP8 2164/4885 |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, LCAT, MTTP | MMP2 1653/4885MMP9 2574/4885MMP8 1349/4885 |
| US-20030109528-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MMP2 1671/4885MMP9 2765/4885MMP8 2164/4885 |
| US-20030087905-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MMP2 1671/4885MMP9 2765/4885MMP8 2164/4885 |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MMP2 1671/4885MMP9 2765/4885MMP8 2164/4885 |
| US-20030100559-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MMP2 1671/4885MMP9 2765/4885MMP8 2164/4885 |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MMP2 1671/4885MMP9 2765/4885MMP8 2164/4885 |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, PCTP | MMP2 1715/4885MMP9 2706/4885MMP8 2576/4885 |
| US-20020120011-A1 | Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, PCTP, DBI | MMP2 1821/4885MMP9 2738/4885MMP8 1444/4885 |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | MMP2 1982/4885MMP9 2690/4885MMP8 1198/4885 |
| US-20030125329-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MMP2 1671/4885MMP9 2765/4885MMP8 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.